Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
You Might also like
- 
					
					Forum fosters dialogue in breast cancerIn October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute. The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians. 
- 
					
					Nurse led micro-suction earwax removal service continues successAt the 2024 Telstra Best of Business Awards in February, Earworx was recognised as the National Championing Health Award winner. Lisa Hellwege, the Clinical Director and Founder of Earworx, expressed her gratitude to the entire team and their patients for their trust and support. Earworx specialises in providing professional earwax removal services led by trained nurses using a procedure called microsuction. 
- 
					
					The role of genomic screening in transforming public healthDr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk. 
 
		
		 
					
																				
					 
					
																				
					